An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivat

Mitapivat, a first‐in‐class, oral, small‐molecule, allosteric activator of the red blood cell‐specific form of pyruvate kinase (PKR), was approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. In this phase I mass balance study in healthy males, we administere...

Descripción completa

Detalles Bibliográficos
Autores principales: Prakash, Chandra, Mangus, Heidi, Yan, Yan, Yang, Hua, Iyer, Varsha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582659/
https://www.ncbi.nlm.nih.gov/pubmed/37596712
http://dx.doi.org/10.1111/cts.13609

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582659/
https://www.ncbi.nlm.nih.gov/pubmed/37596712
http://dx.doi.org/10.1111/cts.13609

Ejemplares similares